Amyris delivers record production of CBG, utilizing 225,000 fermenters

In California, Amyris, Inc. achieved another breakthrough with its production of Cannabigerol (CBG) from fermentation for consumer skincare treatment formulations. Amyris believes that this production run is the largest industrial-scale fermentation-based CBG by any producer to-date. The production was completed utilizing 225,000 fermenters at the facility of Amyris’s Spain-based manufacturing partner.

Amyris’s Lab-to-Market synthetic biology platform continues to demonstrate its capability to engineer yeast to create and produce differentiated high value products. During 2020, Amyris developed its CBG molecule from initial target to production at scale in less than nine months and realized first revenue from CBG in the fourth quarter of 2020. This year’s production volume is spoken for with an expected one million retail units to be sold over the course of the next twelve months.

Amyris’s CBG molecule is the latest addition to its portfolio of natural, sustainably sourced ingredients powering consumer products and contains no trace of THC (or tetrahydrocannabinol). Amyris has completed clinical studies comparing CBG to CBD (cannabidiol) validating the significant performance advantages of CBG over CBD for various skin care applications and treatments. Amyris plans to initially target its CBG towards its consumer brands formulations and a few selective consumer channel partners. Amyris owned consumer brands are among the fastest growing in the clean beauty space with high performing products that are good for our planet.